Califf Sees Real-World Data, Postmarket Surveillance on Horizon for Devices

The GMP Letter
A A
Data from patients will add to the body of evidence used to assess devices, both in the approval process and for postmarket safety, FDA Commissioner Robert Califf told devicemakers.

To View This Article:

Login

Subscribe To The GMP Letter